UK Research and Innovation reported October 23 on BioOrbit’s completed pharmaceutical research mission to the International Space Station. The UK company is studying whether microgravity can support production of concentrated protein crystals that are difficult to manufacture under conditions on Earth.

Its Baby BOX-E platform launched in May and spent approximately six weeks in orbit, according to UKRI. The research explored crystal formation as a possible route to more stable, concentrated formulations. The report also describes a £9.8 million seed funding round supporting the company’s development.

BioOrbit received support through the European Space Agency’s UK business incubation program, delivered with the Science and Technology Facilities Council and other partners. The company has been developing the specialist systems required for orbital manufacturing experiments since joining that program in 2023.

Potential benefits include formulations that might eventually be administered by injection outside a hospital. Those possibilities remain development goals. The announcement does not establish clinical effectiveness, regulatory approval or availability of a new cancer medicine, and the mission itself did not launch in October.